TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Opthea ( (AU:OPT) ).
Opthea Limited has announced the receipt of an A$10.8 million R&D tax incentive from the Australian Taxation Office, which supports their research and development efforts for the financial year 2024/2025. This incentive, part of an Australian Federal Government program, highlights Opthea’s commitment to fiscal discipline and strategic advancement in developing its therapeutic candidate, sozinibercept, potentially enhancing shareholder value and industry positioning.
The most recent analyst rating on (AU:OPT) stock is a Sell with a A$0.05 price target. To see the full list of analyst forecasts on Opthea stock, see the AU:OPT Stock Forecast page.
More about Opthea
Opthea Limited is a biopharmaceutical company focused on developing novel therapies for diseases mediated by VEGF-C and/or VEGF-D. The company’s primary market focus is on advancing its candidate, sozinibercept, which is part of its efforts to innovate within the biopharmaceutical industry.
YTD Price Performance: -25.93%
Technical Sentiment Signal: Sell
Current Market Cap: A$738.8M
Find detailed analytics on OPT stock on TipRanks’ Stock Analysis page.